שווי פעילות לרווח לפני ריבית, מסים ופחת PolyPid (PYPD)

PolyPid Ltd. (PYPD) is developing the PLEX system for prolonged local antibiotic application, which promises high profitability and a steady cash flow. The company achieves cost optimization by outsourcing production and logistics to third-party contractors. The stock's price history reflects an EV/EBITDA of 0.00, while business success relies on a single core product and remains dependent on regulatory decisions.

For PolyPid Ltd. (PYPD), which implements robotics for screening and processing clinical trial data, this indicator serves as a measure of business value relative to its operating profit before depreciation and amortization. By analyzing the EV/EBITDA multiple on the time chart, an investor assesses the total value of assets and debts minus cash, which helps determine the fundamental stability of PolyPid Ltd. (PYPD) amid the capital-intensive automation of laboratories.